Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder

Shahrokh F. Shariat, Raheela Ashfaq, Arthur I Sagalowsky, Yair Lotan

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Purpose: To determine the association of cyclin D1 and E1 expression with bladder cancer presence, clinical and molecular characteristics, and disease progression in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. Methods: Immunohistochemical staining for cyclin D1, cyclin E1, p53, p21, p27, pRB, KI-67, and survivin was performed on a tissue microarray containing specimens from 9 normal controls and 74 patients with Ta, Tis, and/or T1 urothelial cell carcinoma of the bladder. Cyclin D1 and E1 immunoreactivity were considered low when samples showed less than 10% and 30% nuclear reactivity, respectively. Results: Normal bladder urothelium from all 9 control patients showed uniformly intense expression of cyclin D1 and cyclin E1. Cyclin D1 and E1 expression were low in 23 of 74 (31.1%) and 27 of 74 (36.5%) specimens. Kaplan-Meier analyses showed that low expression of cyclin E1 was significantly associated with an increased probability of tumor recurrence and progression in univariate, but not multivariate analysis. Cyclin D1 immunoreactivity was not associated with any pathologic characteristics or clinical outcomes. Low cyclin E1 expression was significantly associated with altered expression of p53, pRB, KI-67, and survivin. Conclusions: Tissue expression of cyclin D1 or E1 seems not to add independent prognostic value to standard features in patients with nonmuscle -invasive urothelial cell carcinoma of the bladder.

Original languageEnglish (US)
Pages (from-to)468-475
Number of pages8
JournalUrologic Oncology: Seminars and Original Investigations
Volume25
Issue number6
DOIs
StatePublished - Nov 2007

Fingerprint

Cyclin D1
Disease Progression
Urinary Bladder
Biomarkers
Cyclins
Carcinoma
Urothelium
Kaplan-Meier Estimate
Urinary Bladder Neoplasms
Multivariate Analysis
Staining and Labeling
Recurrence
Neoplasms

Keywords

  • Cyclin D1
  • Cyclin E1
  • Immunohistochemistry
  • p21
  • p27
  • p53
  • Progression
  • Retinoblastoma
  • Urothelial cell carcinoma of the bladder

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

@article{9c2b170220a549a0892b478cb4d0b6ec,
title = "Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder",
abstract = "Purpose: To determine the association of cyclin D1 and E1 expression with bladder cancer presence, clinical and molecular characteristics, and disease progression in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. Methods: Immunohistochemical staining for cyclin D1, cyclin E1, p53, p21, p27, pRB, KI-67, and survivin was performed on a tissue microarray containing specimens from 9 normal controls and 74 patients with Ta, Tis, and/or T1 urothelial cell carcinoma of the bladder. Cyclin D1 and E1 immunoreactivity were considered low when samples showed less than 10{\%} and 30{\%} nuclear reactivity, respectively. Results: Normal bladder urothelium from all 9 control patients showed uniformly intense expression of cyclin D1 and cyclin E1. Cyclin D1 and E1 expression were low in 23 of 74 (31.1{\%}) and 27 of 74 (36.5{\%}) specimens. Kaplan-Meier analyses showed that low expression of cyclin E1 was significantly associated with an increased probability of tumor recurrence and progression in univariate, but not multivariate analysis. Cyclin D1 immunoreactivity was not associated with any pathologic characteristics or clinical outcomes. Low cyclin E1 expression was significantly associated with altered expression of p53, pRB, KI-67, and survivin. Conclusions: Tissue expression of cyclin D1 or E1 seems not to add independent prognostic value to standard features in patients with nonmuscle -invasive urothelial cell carcinoma of the bladder.",
keywords = "Cyclin D1, Cyclin E1, Immunohistochemistry, p21, p27, p53, Progression, Retinoblastoma, Urothelial cell carcinoma of the bladder",
author = "Shariat, {Shahrokh F.} and Raheela Ashfaq and Sagalowsky, {Arthur I} and Yair Lotan",
year = "2007",
month = "11",
doi = "10.1016/j.urolonc.2006.09.011",
language = "English (US)",
volume = "25",
pages = "468--475",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder

AU - Shariat, Shahrokh F.

AU - Ashfaq, Raheela

AU - Sagalowsky, Arthur I

AU - Lotan, Yair

PY - 2007/11

Y1 - 2007/11

N2 - Purpose: To determine the association of cyclin D1 and E1 expression with bladder cancer presence, clinical and molecular characteristics, and disease progression in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. Methods: Immunohistochemical staining for cyclin D1, cyclin E1, p53, p21, p27, pRB, KI-67, and survivin was performed on a tissue microarray containing specimens from 9 normal controls and 74 patients with Ta, Tis, and/or T1 urothelial cell carcinoma of the bladder. Cyclin D1 and E1 immunoreactivity were considered low when samples showed less than 10% and 30% nuclear reactivity, respectively. Results: Normal bladder urothelium from all 9 control patients showed uniformly intense expression of cyclin D1 and cyclin E1. Cyclin D1 and E1 expression were low in 23 of 74 (31.1%) and 27 of 74 (36.5%) specimens. Kaplan-Meier analyses showed that low expression of cyclin E1 was significantly associated with an increased probability of tumor recurrence and progression in univariate, but not multivariate analysis. Cyclin D1 immunoreactivity was not associated with any pathologic characteristics or clinical outcomes. Low cyclin E1 expression was significantly associated with altered expression of p53, pRB, KI-67, and survivin. Conclusions: Tissue expression of cyclin D1 or E1 seems not to add independent prognostic value to standard features in patients with nonmuscle -invasive urothelial cell carcinoma of the bladder.

AB - Purpose: To determine the association of cyclin D1 and E1 expression with bladder cancer presence, clinical and molecular characteristics, and disease progression in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. Methods: Immunohistochemical staining for cyclin D1, cyclin E1, p53, p21, p27, pRB, KI-67, and survivin was performed on a tissue microarray containing specimens from 9 normal controls and 74 patients with Ta, Tis, and/or T1 urothelial cell carcinoma of the bladder. Cyclin D1 and E1 immunoreactivity were considered low when samples showed less than 10% and 30% nuclear reactivity, respectively. Results: Normal bladder urothelium from all 9 control patients showed uniformly intense expression of cyclin D1 and cyclin E1. Cyclin D1 and E1 expression were low in 23 of 74 (31.1%) and 27 of 74 (36.5%) specimens. Kaplan-Meier analyses showed that low expression of cyclin E1 was significantly associated with an increased probability of tumor recurrence and progression in univariate, but not multivariate analysis. Cyclin D1 immunoreactivity was not associated with any pathologic characteristics or clinical outcomes. Low cyclin E1 expression was significantly associated with altered expression of p53, pRB, KI-67, and survivin. Conclusions: Tissue expression of cyclin D1 or E1 seems not to add independent prognostic value to standard features in patients with nonmuscle -invasive urothelial cell carcinoma of the bladder.

KW - Cyclin D1

KW - Cyclin E1

KW - Immunohistochemistry

KW - p21

KW - p27

KW - p53

KW - Progression

KW - Retinoblastoma

KW - Urothelial cell carcinoma of the bladder

UR - http://www.scopus.com/inward/record.url?scp=36349003416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36349003416&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2006.09.011

DO - 10.1016/j.urolonc.2006.09.011

M3 - Article

C2 - 18047954

AN - SCOPUS:36349003416

VL - 25

SP - 468

EP - 475

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

IS - 6

ER -